Annonce • May 16
CapForce Inc. announced delayed 10-Q filing On 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annonce • Apr 01
CapForce Inc. announced delayed annual 10-K filing On 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annonce • Jan 28
OpGen, Inc., Annual General Meeting, Feb 23, 2026 OpGen, Inc., Annual General Meeting, Feb 23, 2026. Annonce • Nov 15
OpGen, Inc. announced delayed 10-Q filing On 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annonce • Aug 15
OpGen, Inc. announced delayed 10-Q filing On 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annonce • May 17
OpGen, Inc. announced delayed 10-Q filing On 05/16/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annonce • Apr 01
OpGen, Inc. announced delayed annual 10-K filing On 03/31/2025, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Board Change • Mar 10
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. Independent Director Christian-Laurent Bonte was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Feb 14
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. Independent Director Christian-Laurent Bonte was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Annonce • Dec 28
OpGen Provides Nasdaq Minimum Stockholders’ Equity Requirement Non-Compliance Update On December 19, 2024, despite OpGen, Inc. regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market (Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements. Annonce • Nov 15
OpGen, Inc. announced delayed 10-Q filing On 11/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annonce • Aug 22
OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index Annonce • Aug 21
OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index OpGen, Inc. has been dropped from the Nasdaq Composite Index. Annonce • Aug 15
OpGen, Inc. announced delayed 10-Q filing On 08/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annonce • Jun 13
OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq As previously disclosed, the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) notified OpGen, Inc. (the ‘Company’) on June 5, 2023 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In December 2023, the Company appealed such determination to a Nasdaq Hearings Panel, which in February 2024, granted the Company’s request for an additional period to regain compliance with the Minimum Bid Price Rule. On June 5, 2024, the Nasdaq Hearings Panel notified the Company that it had regained compliance with the Minimum Bid Price Rule. In addition, on June 5, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet the alternatives of market value of listed securities or net income from continuing operations. The notice indicated that such delinquency serves as an additional basis for delisting the Company’s securities from Nasdaq. In accordance with the notice, the Company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding such delinquency and the Company’s plan to cure such delinquency. As with the prior notices received by the Company, the most recent notice from Nasdaq has no immediate effect on the listing of the Company’s securities on The Nasdaq Capital Market. There can be no assurance that the Nasdaq Hearings Panel will grant the Company additional time to cure such deficiency or, if additional time is granted, that the Company will be able to regain compliance with the requirements for continued listing. Annonce • Jun 05
Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024 As previously disclosed in a Current Report on Form 8-K filed on May 24, 2024, OpGen, Inc. (the Company") received an additional notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the Form 10-Q") and was therefore not in compliance with Nasdaq Listing Rule 5250(c)(1). Following submission of the Company's plan to cure such delinquency, on May 29, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing subject to the Company filing its Form 10-Q by July 8, 2024. The Company plans to file its Form 10-Q as soon as practicable; however, no assurance can be given as to the definitive date on which such report will be filed. Annonce • May 25
OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024 OpGen, Inc. (‘OpGen’ or ‘the Company’) announced that it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the ‘Form 10-Q’), which serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company’s securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the ‘SEC’). The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the ‘Minimum Bid Price Rule’) and Nasdaq Listing Rule 5250(c)(1) for failing to timely file its Annual Report on Form 10-K for the period ended December 31, 2023 (the ‘Periodic Filing Rule’). As previously disclosed, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule and the Periodic Filing Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-Q in connection with its prior grant of such additional period to regain compliance. The Company has been in communication with Nasdaq to request that the Nasdaq Hearings Panel continue to permit the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule and file the Company’s Form 10-K and for additional time to regain compliance with the Periodic Filing Rule. The notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-Q and plans to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rule. Annonce • May 18
OpGen, Inc. announced delayed 10-Q filing On 05/17/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annonce • May 17
OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per Share OpGen, Inc. (“OpGen” or “the Company”) announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “OPGN.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special Meeting held on May 9, 2024, will increase the market price per share of common stock in order to regain compliance with The Nasdaq Capital Market’s minimum bid price listing requirement of $1.00 per share. Annonce • Apr 24
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K OpGen, Inc. (‘OpGen’ or ‘the Company’) announced that it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the ‘Form 10-K’). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the ‘SEC’). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense. The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the ‘Minimum Bid Price Rule’). As previously disclosed, on February 9, 2024, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-K in connection with its prior grant of an additional period to regain compliance. If the Nasdaq Hearings Panel continues to permit the Company the additional period to regain compliance, the Company expects that it will be required by Nasdaq to file the Form 10-K no later than June 3, 2024 to avoid a delisting determination. The notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Nasdaq Listing Rule. Annonce • Mar 31
OpGen, Inc. announced delayed annual 10-K filing On 03/29/2024, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annonce • Mar 27
Opgen, Inc. Announces Chief Executive Officer Changes OpGen, Inc. announced that David E. Lazar will be appointed as CEO following the initial closing of transaction closing as Oliver Schacht, PhD, resigned as CEO. Mr. Schacht will continue to serve as Executive Vice President of Corporate Development to assist with the transition period following the transactions. David E. Lazar is an experienced private investor who brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions. New Risk • Mar 22
New major risk - Revenue and earnings growth Earnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Market cap is less than US$10m (US$5.13m market cap). Minor Risk Revenue is less than US$5m (US$3.1m revenue). Annonce • Dec 13
OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires As previously disclosed by OpGen, Inc. (the Company"), on June 5, 2023, the listing staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notified the Company that the Company's common stock had failed to maintain aminimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule"). In accordance with Nasdaq ListingRule 5810(c)(3)(A), the Company was provided 180 calendar days, or until December 4, 2023, to regain compliance. On December 6, 2023, the Company received written notification (the December Notice") from the Staff indicating that, based upon (i) the Company's continued non-compliance with the Minimum Bid Price Rule and (ii) the Company's inability to meet Nasdaq's initial listing requirement for maintaining a minimum of stockholders' equity, the Staff determined that the Company was not eligible for an additional 180 day extension to meet the Minimum Bid Price Rule. As a result, the Staff determined to delist the Company's securities from Nasdaq, effective December 15, 2023, unless the Company timely requested an appeal to a Nasdaq Hearings Panel (the Panel"). On December 11, 2023, the Company submitted a request for a hearing before the Panel, which request stayed any suspension or delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires. Subject to the Panel's availability, the hearing is expected to occur in the first quarter of 2024. As a result of the pending appeal, the December Notice has no immediate effect on the listing of the Company's common stock at this time. At the hearing, the Company intends to present a plan to regain compliance with the Minimum Bid Price Rule and request that the Panel allow the Company additional time within which to regain compliance. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol OPGN" pending the outcome of the hearing. Although the Company intends to submit a comprehensive plan to regain compliance, there can be no assurances that the Panel will grant the Company's request for continued listing or that the Company will be able to demonstrate compliance with all applicable requirements for continued listing on The Nasdaq Capital Market within any extension of time that may be granted by the Panel. If the Company's common stock is delisted, it could be more difficult to buy or sell the Company's common stock or to obtain accurate quotations, and the price of the Company's common stock could suffer a material decline. Delisting could also impair the Company's ability to raise capital. Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.46 loss per share (vs US$5.92 loss in 3Q 2022) Third quarter 2023 results: US$0.46 loss per share (improved from US$5.92 loss in 3Q 2022). Revenue: US$699.0k (up 56% from 3Q 2022). Net loss: US$4.06m (loss narrowed 71% from 3Q 2022). Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Annonce • Oct 12
OpGen, Inc. announced that it expects to receive $1 million in funding OpGen, Inc. announced that it has entered into a Preferred Stock Purchase Agreement with a single investor pursuant to which the company agreed to issue 1,000 shares of the Company’s Series D Preferred Stock, par value $0.01 per share at a price of $1,000 per share for aggregate gross proceeds of $1 million before deducting offering expenses on October 11, 2023. The transaction is expected to close on or about October 13, 2023. Annonce • Aug 04
OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023 OpGen, Inc. announced that they will report Q2, 2023 results at 12:30 PM, US Eastern Standard Time on Aug 10, 2023 Annonce • Jun 12
OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement On June 5, 2023, OpGen, Inc. received written notice from The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share over the prior 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq’s Listing Rules, the Company has 180 calendar days to regain compliance with Nasdaq’s minimum bid price requirement. If the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, if the Company provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period. Annonce • May 09
OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023 OpGen, Inc. announced that they will report Q1, 2023 results at 4:30 PM, US Eastern Standard Time on May 15, 2023 Annonce • May 06
OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million. OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 4,495,825
Price\Range: $0.7785
Security Name: Common Warrants
Security Type: Equity Warrant
Securities Offered: 4,495,825 Annonce • Jan 19
OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022 OpGen, Inc. announced preliminary unaudited revenue for 2022. Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its third quarter earnings call. Annonce • Jan 09
OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,586,207
Security Name: Series A-1 Warrants
Security Type: Equity Warrant
Securities Offered: 2,586,207
Security Name: Series A-2 Warrants
Security Type: Equity Warrant
Securities Offered: 2,586,207
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 2,586,207 Reported Earnings • May 14
First quarter 2021 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2020) First quarter 2021 results: Net loss: US$14.9m (loss widened 276% from 1Q 2020).